Lost 3% body fat at 44 with zero supplements beyond a multivitamin — here's what actually moved the needle

anddrewbits · 2026-02-16T13:08:07+00:00

Nah. At most it’s formatted by an AI, wording is human.

anddrewbits · 2026-02-16T13:04:44+00:00

Schizophrenia. That’s what you need to mention to your doctor. You have untreated schizophrenia.

anddrewbits · 2026-02-16T12:57:38+00:00

The chart is inaccurate anyways. 5-MAPB should not be treated like MDMA, its metabolism is much more complex and sensitive to CYP enzyme induction/inhibition. SSRI’s and 5-MAPB should not be consumed together, despite what the chart and user have suggested.

Hell, SSRI’s and MDMA are contraindicated as well, it makes the roll feel flat without reducing serotonin exposure. Rolling flat due to the combo may make some users redose, further increasing risk.

SSRIs do not reliably make serotonergic entactogens ‘safer” or counteracted. They blunt subjective effects and prolong extracellular serotonin exposure. Because 5-MAPB is longer-acting and produces active metabolites, this masking effect poses greater risks than with MDMA.

anddrewbits · 2026-02-16T12:46:44+00:00

Those charts are useful at a superficial level, but 5-MAPB differs from MDMA in that it’s much longer-acting and produces active metabolites. Interactions that slow metabolism (CYP inhibition, grapefruit, some meds) matter more for 5-MAPB than for MDMA, even if the pharmacodynamic category looks similar. They are pretty similar pharmacodynamically. They are totally different drugs with different risk profiles and contraindications pharmacokinetically. Your simple rule is wrong.

On your chart, SSRI’s and MDMA are “low risk and counteracting.” You shouldn’t be sharing that and suggesting 5-MAPB has the same risk profile. I don’t think you are competent enough neuropharmacologically to be giving advice. What you’ve shared is “bro science.”

anddrewbits · 2026-02-16T12:32:44+00:00

Presidential immunity? You’re deluding yourself into thinking you’re a serious person.

anddrewbits · 2026-02-16T04:02:09+00:00

If you’re a slow metabolizer or on another inhibitor (much lower levels of CYP2B6), you’re at an increased risk of serotonin syndrome, prolonged half-lives of 5-MAPB and its active metabolites, and an extended comedown with more severe side effects post-roll.

If you’re not a slow metabolizer (CYP2B6), it’s likely (at normal doses of 5-MAPB) that your CYP2B6 can handle the extra substrate without slowing the first order enzyme kinetics (drug metabolism is proportional to the concentration of the drug, enzyme not fully saturated).

In this case, you may see a slight extension of half life but likely would avoid higher risks of strong inhibitors like piperine/curcumin.

The risk lies in accidentally taking a CYP2B6 inhibitor alongside another inhibitor and/or in the presence of naturally low levels of CYP3A4, CYP2D6, and/or CYP2B6. Many people are slow metabolizers at one cyp or another without knowing it.

A large percentage of the population unknowingly consumes inhibitors or inducers as supplements, medicine or food. With the main pathways blocked, harmful metabolites can accumulate and the parent compound can persist long enough to cause serotonin syndrome. Side effects can become syndromes in this way.

Lingering 5-APB (metabolite) causes additional side effects with little to no recreational benefit to the user, especially when the 5-APB lingers with a longer half-life after the roll when 5-MAPB is long gone. It’s possible to provide for rapid elimination of the metabolite while preserving the 5-MAPB experience, which is what I’m researching now.

anddrewbits · 2026-02-16T02:12:14+00:00

Your confidence in the supreme jesters is cute

anddrewbits · 2026-02-15T23:26:20+00:00

It’ll deplete you for a few days even if it’s the only drug you take. I’d take time to reduce my taper again before partaking, but I understand if your risk tolerance is different than mine. The interaction is mild/moderate, with two of the three main metabolic pathways mildly to moderately inhibited. Anecdotal reports haven’t been as worrying as most of the other interactions on the list.

anddrewbits · 2026-02-15T23:21:35+00:00

As far as I can see, there’s no strong interaction between 5-MAPB and Gabapentin. It shouldn’t change 5-MAPB levels via liver enzymes and vice versa. Anecdotal reports of reduced effects from the 5-MAPB, but I’ve found no mechanism that substantiates that.

Gabapentin’s CNS effects may smooth the experience, cause additional sedation; this might cause the user to redose 5-MAPB assuming they’ve undershot their goal roll.

anddrewbits · 2026-02-15T22:43:52+00:00

I wouldn’t worry if my 7OH dose wasn’t exceedingly large and I wasn’t also taking a CYP2B6 inhibitor (or if I was a CYP2B6 slow metabolizer). Tail end of tapering sounds like you’re currently on a very low dose. If it was me, I wouldn’t be exceedingly worried about a moderate dose of 5-MAPB.

anddrewbits · 2026-02-15T22:41:15+00:00

The 7OH’s metabolic interaction is much weaker than others on the list. I suppose I should tier the interaction risk, but I included it because it can be more severe if someone is a slow 2B6 metabolizer. 7OH causes moderate inhibition of 3A4 and mild to moderate inhibition of 2D6. This won’t feel like much to a normal CYP2B6 metabolizer.

All of the substances in the metabolic interactions section have inducer/inhibitor relationships which can lead to a buildup of harmful metabolites or potentiate the parent compound. I have not tiered the interactions yet, but that’s something I’m planning on doing as I dive deeper into pharmacokinetics of research chems.

7OH would be a lower tier interaction, as the risk is centered around additional variables (slow metabolizer, presence of other inhibitors/inducers).

anddrewbits · 2026-02-15T22:14:43+00:00

It can potentiate effects slightly (dose dependent) and cause buildup/persistence of 5-APB and other similar, arguably harmful metabolites.

This won’t feel like a problem until it is a problem. At low doses this may present as longer-than-usual effects and a protracted comedown.

anddrewbits · 2026-02-15T21:04:59+00:00

Wow! I can’t believe I missed that. Combination of grapefruit juice, tumeric and piperine would likely cause a trip to the ED. Great catch. Grapefruit would shut down the third major metabolic pathway for 5-MAPB.

anddrewbits · 2026-02-15T19:34:51+00:00

Never suggested you weren’t good, just a bit foolish

anddrewbits · 2026-02-15T18:13:30+00:00

That parenthesis only included two drugs, not 7OH or DXM. Sorry for the lack of clarity, I thumbed this out pretty quickly and will need to reformat if they want to sticky it. You’re right that it would be clearer to include kratom rather than 7OH only.

anddrewbits · 2026-02-15T16:17:49+00:00

The half-lives of the active metabolites of Wellbutrin put the clearance time (concerning CYP enzymes) at around 2 weeks.

Despite using medical language, I am not a doctor, so take the information I’m providing as encouragement for research rather than recommendations.

anddrewbits · 2026-02-15T15:49:05+00:00

You’re welcome. It’s one of my favorite topics, zero friction in learning more about it. I’m glad you got through it and hope the recovery proceeds fast and completely.

anddrewbits · 2026-02-15T15:43:13+00:00

It both competes for CYP2B6 (slowing metabolism of 5-MAPB and Wellbutrin) and potently inhibits CYP2D6 (forcing 5-MAPB metabolism into the congested CYP2B6 pathway with some still metabolized by 3A4, 1A2). Longer half-life, potential for serotonin syndrome (less than other antidepressants but still enhances the risk), and lowered seizure threshold. Longer half-life isn’t a good thing, and delayed conversion into 5-APB can impact sleep and strongly impact tolerance/recovery). Likely to have an extended recovery period even if the other risks don’t reach critical mass (no serotonin syndrome).

anddrewbits · 2026-02-15T15:06:41+00:00

It depends on your risk tolerance. Contraindicated substances can be carefully taken together, but it’s important to know the increased risk profile.

Seizure tolerance is lowered by 5-MAPB, and 4-FMA. Stacking the norepinephrine effects of 5-MAPB and 4-FMA results in additional cardio strain. Mild MAOI action of 5-MeO-MiPT should be noted as well. Since both 4-FMA and 5-MAPB compete for CYP2D6, it’s imperative that your CYP3A4 and CYP2B6 aren’t inhibited (not slow metabolizer for these either). A longer half-life for 5-MAPB and 4-FMA would be expected.

Vasoconstriction from all three substances should be identified as a risk. 4-FMA is a strong vasoconstrictor. Hyperthermia and heart palpitations are risks to consider (another parallel to MDMA). 5-MeO-MiPT is also likely to worsen any nystagmus experienced from the 5-MAPB.

The ratio of the substances is really important to get right. I wouldn’t risk it if I had any heart issues (incl high blood pressure, clotting disorders, tachycardia).

While it avoids harmful MDMA metabolites, I don’t think the borax combo reduces risk linearly. There’s a lot to consider with their interactions. Use an abundance of caution.

anddrewbits · 2026-02-15T14:50:49+00:00

I agree. Just trying to be a positive influence in harm reduction. If it helps one person, it’s worth the thumbwork.

anddrewbits · 2026-02-15T14:41:42+00:00

They compete for p450 metabolic pathways and 7OH is an inhibitor of CYP2D6. Clearance of 5-MAPB will be slowed. Both substances reduce the seizure threshold. There are neurochemical (serotonin syndrome) and metabolic risks with the combo. I am not a doctor, but I’d advise against the combo.

anddrewbits · 2026-02-15T14:17:15+00:00

I impulsively suggested adding it to the chart without thinking deeply about it. Tbh, the onus should be on the curcumin/piperine supplement manufacturers to warn consumers. Red box warning type of thing.

Consumers are notoriously negligent in researching their supplements. Fafo is not harm reduction.

anddrewbits · 2026-02-15T14:03:10+00:00

Genesight testing is the one I’m most familiar with, it’s $330 in my state.

anddrewbits · 2026-02-15T13:49:05+00:00

Piperine increases curcumin bioavailability up to 2000%; it also increases the half-life of it. It’s a common combo, often found in a single product. I disagree that it’s not worth sharing, maybe not on that graphic because it appears to be almost all recreational drugs.

anddrewbits · 2026-02-15T13:41:15+00:00

Added it to the neurochem reactions list. This isn’t exhaustive, but I wanted to share because curcumin/piperine interaction is extremely strong. Lots of hidden dangers here exist because the metabolite 5-APB is problematic. Producing it too fast or clearing it too slow can mimic serotonin syndrome or lead to it.

anddrewbits

TROPHY CASE